– December 1, 2009
December 1, 2009
View Issues
-
Romiplostim and Marrow Fibrosis
Thrombopoietin receptor agonists such as romiplostim and eltrombopag have recently been approved to raise platelet counts in patients with immune thrombocytopenic purpura (ITP). One unusual side effect has been increased bone marrow reticulin fibrosis. -
Pretreatment Comprehensive Assessment for Elderly Lymphoma Patients
Elderly patients with diffuse large cell lymphomas were assessed for the presence of various factors that might influence clinical outcomes from aggressive therapy. -
Predicting Survival by PET/CT Response to Presurgical Chemoradiation in GE Cancer
The authors assessed 151 consecutive patients with gastroesophageal adenocarcinoma who had chemoradiation and surgery. -
Neutropenia and Survival in NSCLC
Examining data from a randomized trial of two different chemotherapy regimens for non-small cell lung cancer, Kishida et al found that chemotherapy-induced neutropenia is a predictor of better survival. The authors call for future trials in which dose increases are employed in the absence of neutropenia or other chemotherapy-induced toxicity. -
Metronomic Vinorelbine
Metronomic chemotherapy implies the use of a lower-dose agent over protracted periods of time. In the current phase I trial, vinorelbine was administered orally, three times weekly to 62 patients at various escalating doses, and it was determined that 50 mg/dose was optimal. -
Clinical Briefs in Primary Care Supplement
-
Pharmacology Watch
Efficacy of once-daily insulin, aldo-sterone use in heart failure, erectile dysfunction Clinical Practice Guidelines, and FDA Actions.